MedTrace Logo

Intraoperative Dialysis in Liver Transplantation

NCT01575015 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2017-02-07

No results posted yet for this study

Summary

Patient with liver failure waiting for liver transplantation are often hospitalized and commonly supported in an intensive care unit prior to surgery. These patients are sick, and in addition to the complications of a failing liver, other organs such as the kidneys often fail as well. As a consequence, these patients are at an increased risk for complications related to their kidney failure during their liver transplantation procedure. One potential method to diminish the risk of these complications is to provide dialysis support to these patients during their liver transplantation in the operating theater in the form of continuous renal replacement therapy (CRRT). While this is increasingly being performed and is theoretically appealing, there is very little information to support this practice. In addition, the use of CRRT during surgery is not entirely without risk. The investigators have performed two preliminary studies on the use of CRRT during liver transplantation and our data would strongly support the need to conduct further higher-quality studies to better evaluate its feasibility, safety and usefulness. Our proposed study is for a randomized trial comparing the use of CRRT during surgery with standard supportive care in sick patients with liver failure scheduled to receive a liver transplantation.

Conditions

  • Liver Failure
  • Acute Kidney Disease
  • Multi-organ Failure

Interventions

DEVICE

Continuous renal replacement therapy (CRRT)

Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation

PROCEDURE

Standard intraoperative support

Patients allocated to standard intraoperative support will receive usual care (no CRRT).

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Sean M Bagshaw, MD, MSc · Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-12-11
Completion
2015-12-11

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01575015 on ClinicalTrials.gov